We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Genomic Research Kit Simplifies Exome Studies

By LabMedica International staff writers
Posted on 04 Oct 2015
Print article
An exciting new tool is now available for biotech researchers working in the field of genomic analysis.

The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is comprised of the most functionally relevant and best understood 1% of the human genome. Targeted sequencing is a powerful technique allowing researchers to focus their analysis on this critical portion of the genome.

Roche NimbleGen (Madison, WI, USA) has announced the release of its SeqCap EZ MedExome Target Enrichment Kit. This kit is a new exome solution that queries the entire human exome with enhanced coverage for exons of disease-associated gene regions. The design targets the genome assembly GRCh38/hg38 (coordinates for hg19 annotation are also available) with comprehensive sequencing coverage of medically-relevant regions and protein coding regions. The product has been extensively optimized in design, empirical rebalancing, and manufacturing to increase coverage in hard-to-sequence regions for a more uniform and complete exome.

The SeqCap EZ MedExome kit produces greater than 85% on-target rate, demonstrates high uniformity across the targeted region with better than 98% sensitivity for SNP detection and greater than 99% specificity for SNP allele classification. Additionally, the SeqCap EZ MedExome kit is compatible with a mitochondria-specific design which enables extended exome testing in cases where the mitochondria are of interest.

SeqCap EZ products enable a revolutionary process for the enrichment of selected genomic regions from full complexity human genomic DNA in a single step. Developed to eliminate the necessity of setting up thousands of PCR reactions, Sequence Capture allows for parallel enrichment of target regions in a single experiment.

"The release of the SeqCap EZ MedExome Target Enrichment Kit is an example of Roche Sequencing's commitment to further the evolution of genomic medicine," said Rebecca Selzer, president of Roche NimbleGen. "Immense interest in this design from our customers worldwide led to initiation of an early product evaluation process resulting in more than 40 evaluations across 11 countries globally prior to launch. This technology puts some of the most powerful tools of modern genomics to use in more laboratories around the world and is an invaluable asset in furthering the research of disease-associated mutations, while minimizing the need for costly retesting and follow-up sequencing."

Related Links:

Roche NimbleGen

Gold Supplier
HDL Subfractions Kit
Lipoprint HDL Subfractions Kit
Semi-Automatic Biochemistry Analyzer
Lung Cancer Molecular Diagnostic Test

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more


view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.